Pervasive Sensing and AI in Intelligent ICU
Pervasive Sensing and Artificial Intelligence in Intelligent ICU Subtitles: -Intelligent Intensive Care Unit (I2CU): Pervasive Sensing and Artificial Intelligence for Augmented Clinical Decision-making -ADAPT: Autonomous Delirium Monitoring and Adaptive Prevention
University of Florida
400 participants
May 24, 2021
OBSERVATIONAL
Conditions
Summary
Important information related to the visual assessment of patients, such as facial expressions, head and extremity movements, posture, and mobility are captured sporadically by overburdened nurses, or are not captured at all. Consequently, these important visual cues, although associated with critical indices such as physical functioning, pain, delirious state, and impending clinical deterioration, often cannot be incorporated into clinical status. The overall objectives of this project are to sense, quantify, and communicate patients' clinical conditions in an autonomous and precise manner, and develop a pervasive intelligent sensing system that combines deep learning algorithms with continuous data from inertial, color, and depth image sensors for autonomous visual assessment of critically ill patients. The central hypothesis is that deep learning models will be superior to existing acuity clinical scores by predicting acuity in a dynamic, precise, and interpretable manner, using autonomous assessment of pain, emotional distress, and physical function, together with clinical and physiologic data.
Eligibility
Inclusion Criteria3
- aged 18 or older
- admitted to UF Health Shands Gainesville ICU ward
- expected to remain in ICU ward for at least 24 hours at time of screening
Exclusion Criteria4
- under the age of 18
- on any contact/isolation precautions
- expected to transfer or discharge from the ICU in 24 hours or less
- unable to provide self-consent or has no available proxy/LAR
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
continuous video monitoring
continuous accelerometer monitoring of patient movements
continuous environmental noise monitoring
continuous environmental light monitoring
continuous environmental air quality monitoring
continuous EKG monitoring
continuous vitals monitoring (heart rate, oxygen saturation)
blood and urine samples collected once on Day 1 and once on Day 2
done daily on delirious patients to subtype delirium
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05127265